The US FDA has approved difamilast, a topical phosphodiesterase 4 inhibitor for the treatment of mild to moderate atopic dermatitis in patients 2 years of age and older. Clinical evidence In a clinical study involving 612 patients, difamilast 1% demonstrated a statistically significant higher proportion of patients achieving Investigator’s Global Assessment success compared to vehicle at four weeks. Dosage and administration Available as a topical oinment Apply a thin layer of difamilast 1% twice daily to affected areas and rub in completely Contraindications None Adverse reactions Nasopharyngitis Source : FDA Did you find this FDA Alert interesting?
##Disclaimer## The content provided on Docplexus is intended for educational purposes only. While we strive to ensure its accuracy, we make no warranties, explicit or implied, about the suitability, reliability, or adequacy of the…
